protein targeting


Also found in: Wikipedia.

protein targeting

Any mechanism by which proteins that have been manufactured by cells are distributed to specific cellular membranes or organelles.
References in periodicals archive ?
IBI302 is a novel recombinant fully human bi-specific fusion protein targeting both vascular endothelium growth factor (VEGF) and complement proteins.
Among them are assessing the contributions of motor enzymes and microtubule dynamics to mitotic chromosome motions, cell sheet morphogenesis: dorsal closure in Drosophila melanogaster as a model system, ribosomal stalling during translation: providing substrates for ribosome-associated protein quality control, mechanisms of tail-anchored membrane protein targeting and insertion, sex and gender differences in the outcomes of vaccination over the life course.
When researchers injected the Cas9RNA protein targeting the mutation into already fertilized zygotes, they found that 67% of the resulting embryos had two normal copies of the MYBPC3 gene.
Multistate GTPase control co-translational protein targeting.
Xin Zhang presents his chemistry thesis, presented to the California Institute of Technology, on Multistate GTPase Control Co-translational Protein Targeting, which is concerned with protein behavior at the molecular level.
The researchers injected a protein targeting lymphotoxin into cancer-susceptible mice.
Unlike the first edition, this second edition places emphasis on protein targeting to cellular compartments in both prokaryotic and eukaryotic systems.
In parallel, Fusion Pharmaceuticals gained access to a centyrin-based targeting molecule in preclinical development that has the potential to deliver isotopes to several cancer types and access to the centyrin protein targeting platform in two licensing agreements with Janssen Biotech, Inc.
Among the topics are epigenetics in skeletal muscle development, microRNAs and cancer, pediatric cancers, and the potential of heat shock protein targeting for human therapy.
Health care company Allergan Inc (NYSE:AGN) and Swiss biotech company Molecular Partners AG reported jointly on Wednesday the execution of a licence agreement for MP0112, a phase II proprietary therapeutic DARPin protein targeting VEGF.